Advertisement
New Zealand markets closed
  • NZX 50

    12,105.29
    +94.63 (+0.79%)
     
  • NZD/USD

    0.5961
    -0.0044 (-0.74%)
     
  • ALL ORDS

    8,153.70
    +80.10 (+0.99%)
     
  • OIL

    81.57
    +0.22 (+0.27%)
     
  • GOLD

    2,213.80
    +1.10 (+0.05%)
     

The Zacks Analyst Blog Highlights: Bristol-Myers, ConocoPhillips, Qualcomm, General Motors and Marathon

For Immediate Release

Chicago, IL –February 12, 2019 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include: Bristol-Myers BMY,ConocoPhillips COP,Qualcomm QCOM, General Motors GM and Marathon Petroleum MPC.

Here are highlights from Monday’s Analyst Blog:

Top Analyst Reports for Bristol-Myers, ConocoPhillips and Qualcomm

The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including Bristol-Myers, ConocoPhillips and Qualcomm. These research reports have been hand-picked from the roughly 70 reports published by our analyst team today.

ADVERTISEMENT

You can see all of today’s research reports here >>>

Buy-rankedBristol-Myers’ shares have underperformed the Zacks Large Cap Pharmaceuticals industry over the past six months, -15.5% vs. +2.1%. Bristol-Myers topped fourth-quarter earnings on robust sales of Opdivo and Eliquis. Bristol-Myers' blockbuster immuno-oncology drug

The Zacks analyst thinks Opdivo’s performance is being boosted by the uptake in new indications in the United States - first line RCC and adjuvant melanoma. Eliquis is expected to drive growth, owing to increases in market share in the novel oral anticoagulant market. The label expansion of other drugs like Sprycel and Empliciti should further boost sales.

The recently announced acquisition of Celgene should strengthen the oncology franchise. However, the company’s voluntary withdrawal of the sBLA seeking approval of Opdivo+Yervoy as a treatment for first-line NSCLC with tumor mutational burden greater or equal to 10 mutations/megabase following discussions with the FDA was disappointing given the market potential.

(You can read the full research report on Bristol-Myers here >>>).

Shares of ConocoPhillips are up 24% over the past year, outperforming the Zacks U.S. Integrated Oil industry, which has increased +0.1% over the same period. The Zacks analyst emphasizes that in terms of production and proved reserves, ConocoPhillips is the largest oil and gas exploration and production (E&P) player in the world.

Notably, there are significant opportunities for the upstream energy player in the Eagle Ford where it owns about 3,400 undrilled locations. In fact, strong focus on two other prospective resources like Delaware basin and Bakken shale is expected to help ConocoPhillips achieve its target of more than 25% CAGR of production through 2017 to 2019.

The company recently reported strong fourth-quarter 2018 earnings, thanks to robust volumes from the unconventional assets. However, the firm’s projection of higher production and operating costs is likely to hurt its bottom line. Moreover, since majority of ConocoPhillips’ production comprises oil, the volatile crude pricing scenario could hurt the company’s operations.

(You can read the full research report on ConocoPhillips here >>>).

Qualcomm’s shares have lost 23.4% over the past year, underperforming the Zacks Wireless Equipment industry, which has lost -5.4% over the same period. Qualcomm reported mixed first-quarter fiscal 2019 results wherein the bottom line beat expectations but the top line missed the same. The company expects improving conditions for its chip business in the second half of fiscal 2019 on the back of new product launches.

The Zacks analyst likes how the company continues to execute its strategic objectives, including driving the global transition to 5G, protecting its intellectual property rights and expanding into new industries and product categories to stoke growth. Qualcomm’s Snapdragon 855 is gaining significant momentum with more than 100 design wins in development.

Aggressive competition in the mobile phone chipset market is likely to hurt profitability. Over the past quarters, Qualcomm’s results were adversely impacted by ongoing legal disputes with Apple. It is also facing competitive threat from its closest rival, Intel.

(You can read the full research report on Qualcomm here >>>).

Other noteworthy reports we are featuring today include General Motors and Marathon Petroleum.

Is Your Investment Advisor Fumbling Your Financial Future?

See how you can more effectively safeguard your retirement with a new Special Report, “4 Warning Signs Your Investment Advisor Might Be Sabotaging Your Financial Future.”

Click to get it free >>

Media Contact

Zacks Investment Research

800-767-3771 ext. 9339

support@zacks.com                       

https://www.zacks.com

Past performance is no guarantee of future results. Inherent in any investment is the potential for loss. This material is being provided for informational purposes only and nothing herein constitutes investment, legal, accounting or tax advice, or a recommendation to buy, sell or hold a security. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. It should not be assumed that any investments in securities, companies, sectors or markets identified and described were or will be profitable. All information is current as of the date of herein and is subject to change without notice. Any views or opinions expressed may not reflect those of the firm as a whole. Zacks Investment Research does not engage in investment banking, market making or asset management activities of any securities. These returns are from hypothetical portfolios consisting of stocks with Zacks Rank = 1 that were rebalanced monthly with zero transaction costs. These are not the returns of actual portfolios of stocks. The S&P 500 is an unmanaged index. Visit https://www.zacks.com/performance for information about the performance numbers displayed in this press release.


Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
 
Bristol-Myers Squibb Company (BMY) : Free Stock Analysis Report
 
QUALCOMM Incorporated (QCOM) : Free Stock Analysis Report
 
Marathon Petroleum Corporation (MPC) : Free Stock Analysis Report
 
To read this article on Zacks.com click here.
 
Zacks Investment Research